STOCK TITAN
  1. Home
  2. News
  3. CYBN

Cybin Inc - CYBN STOCK NEWS

Welcome to our dedicated news page for Cybin (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cybin's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cybin's position in the market.

News
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Rhea-AI Summary
Cybin Inc. CEO, Doug Drysdale, is set to participate in a panel at the 27th Annual Milken Institute Global Conference on May 8, 2024. The company aims to revolutionize mental healthcare with psychedelic-based treatment options. The conference will focus on global challenges, with Cybin sharing its vision for transforming mental health treatment through innovative therapies like CYB003 and CYB004.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
News
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Rhea-AI Summary
Cybin Inc. announces the publication of a research manuscript in the Journal of Medicinal Chemistry, exploring structure-activity relationships of 2C-X analogs. The study led to the discovery of CYB210010, a potent serotonin 5-HT2 receptor agonist with favorable properties, showcasing the company's commitment to revolutionizing mental healthcare through innovative psychedelic-based treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
News
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Rhea-AI Summary
Cybin Inc. announces the grant of an additional U.S. patent to support its CYB003 Breakthrough Therapy Program for Major Depressive Disorder. The patent is expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company's proprietary deuterated psilocybin analog program. Cybin's patent portfolio now consists of over 50 granted patents and 170 pending applications. The Company plans to begin enrollment for a multinational Phase 3 program evaluating CYB003 in Major Depressive Disorder by mid-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
News
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
Cybin Inc. announces CEO Doug Drysdale's presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. The webcast will be live on April 16, 2024, at 1:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags
conferences
-
News
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
Rhea-AI Summary
Cybin Inc. announces the successful closing of a private placement, raising U.S.$150,000,000 for drug development activities and general corporate purposes. The company sold 348,837,210 common shares at U.S.$0.43 per share, with participation from various institutional investors. The funds will primarily support the development of CYB003, a potential treatment for Major Depressive Disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
News
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Rhea-AI Summary
Cybin Inc. announced its participation in the upcoming Public Ventures Discovery Day on March 19, 2024, where Doug Drysdale, the CEO, will engage in a fireside chat. The event aims to showcase Cybin's innovative psychedelic-based treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences
News
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Rhea-AI Summary
Cybin Inc. announces the initiation of a Phase 2 study for CYB004, a proprietary deuterated DMT molecule, in the treatment of Generalized Anxiety Disorder (GAD). The study aims to provide a scalable, short-duration psychedelic experience for patients, potentially disrupting negative thought patterns. Topline Phase 2 safety and efficacy data are expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
clinical trial
-
News
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Rhea-AI Summary
Cybin Inc. announces positive End-of-Phase 2 meeting with FDA for CYB003, a deuterated psilocybin analog for Major Depressive Disorder. Phase 3 program to commence mid-2024 with 15 U.S. clinical trial sites targeted. CYB003 shows robust improvement in depression symptoms with 75% of patients in remission after two doses. Breakthrough Therapy Designation granted for CYB003 by FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
clinical trial
-
News
Announces Oversubscribed Private Placement of U.S. $150 Million
Rhea-AI Summary
Cybin Inc. announces a proposed private placement of 348,837,210 common shares at a price of U.S.$0.43 per share, aiming to raise U.S.$150,000,000 for drug development activities and general corporate purposes. The offering is oversubscribed and led by Deep Track Capital, with participation from other institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
none
News
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Rhea-AI Summary
Cybin Inc. receives Breakthrough Therapy Designation from the FDA for CYB003, a psychedelic-based therapy for Major Depressive Disorder. Positive Phase 2 trial results show significant improvement in depression symptoms with 75% remission after two doses. The company plans to progress to a Phase 3 study in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
none
Stock CYBN logo
Cybin Inc

NYSE:CYBN

CYBN Rankings

#3532 Ranked by Market Cap
#556 Ranked by Stock Gains
N/A Ranked by Dividends

CYBN Stock Data

288.57M
322.71M
6.66%
23.08%
3.03%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Toronto